The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 250-page report you will receive 145 charts– all unavailable elsewhere.
The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Rare Disease Drugs Market forecasts from 2019-2029
• Revenue forecasts for the global rare disease drugs market by application from 2019-2029:
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases
• Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:
• Avonex
• Copaxone
• Gleevec
• Imbruvica
• MabThera/Rituxan
• Opdivo
• Rebif
• Revlimid
• Sprycel
• Tasigna
• Velcade
• Other Drugs
• Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:
• North America (US, Canada)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (Japan, China, India, South Korea)
• RoW (Brazil, Mexico, South Africa, Russia)
• Profiles and discussion on the leading companies in the rare disease drugs market:
• AbbVie
• Bristol-Myers Squibb (BMS)
• Celgene
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda
• Teva
• Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.
• SWOT Analysis and Porter’s Five Forces analysis of the global rare disease drugs market
• Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.
• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2019 to 2029?
• What are the leading national market potentials from 2019 to 2029?
• How is the rare disease drugs market evolving?
• What is driving and restraining the rare disease drugs market?
• What are the market shares of each segment of the overall rare disease drugs market?
• How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Rare Disease Drugs Market. You find data, trends and predictions.
Buy our report today Global Rare Disease Drugs Market Analysis: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Rare Disease Drugs Market Overview
1.2 Global Rare Disease Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methods of the Study
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Rare Diseases
2.1 What Are Rare Diseases?
2.2 Characteristics of Rare Diseases
2.3 Rare Disease Facts and Statistics
2.4 Enduring Challenges of Rare Diseases
2.5 Types of Rare Diseases
2.5.1 Rare Oncology Diseases
2.5.2 Rare Metabolic Diseases
2.5.3 Rare Neurologic Diseases
2.5.4 Rare Hematology Diseases
2.5.5 Rare Infectious Diseases
2.5.6 Other Rare Diseases
3. Rare Diseases: World Market 2019-2029
3.1 Rare Disease Drugs Market Overview, 2018
3.2 The World Rare Disease Drugs Market
3.3 World Rare Disease Drugs Market: Sales Forecast 2019-2029
3.4 Changing Market Shares by Region 2019-2029
4. Rare Diseases: Qualitative Analysis 2019-2029
4.1 Rare Disease Drugs Market: Drivers 2019-2029
4.1.1 Increase in Prevalence of Rare Diseases
4.1.2 High Investment in Rare Disease Drugs R&D
4.1.3 Increase in Number of Product Approvals
4.1.4 Growing Support of Government for Rare Diseases
4.2 Rare Disease Drugs Market Restraints: 2019-2029
4.2.1 Challenges in Treatment
4.2.2 Challenges in Research and Development
4.2.3 Stringent Government Regulations
4.3 Rare Disease Drugs Market Opportunities: 2019-2029
4.3.1 Progress in Diagnostics and Therapeutics
4.3.2 Orphan Drug Opportunities
4.3.3 IRDiRC Guidelines and Policies
5. Rare Disease Drugs Market by Drugs, 2019-2029
5.1 Market Overview
5.2 Market Forecast 2019-2029
5.2.1 Revlimid: Market Forecast, 2019-2029
5.2.2 MabThera/Rituxan: Market Forecast, 2019-2029
5.2.3 Opdivo: Market Forecast, 2019-2029
5.2.4 Imbruvica: Market Forecast, 2019-2029
5.2.5 Sprycel: Market Forecast, 2019-2029
5.2.6 Avonex: Market Forecast, 2019-2029
5.2.7 Tasigna: Market Forecast, 2019-2029
5.2.8 Copaxone: Market Forecast, 2019-2029
5.2.9 Rebif: Market Forecast, 2019-2029
5.2.10 Gleevec: Market Forecast, 2019-2029
5.2.11 Velcade: Market Forecast, 2019-2029
5.2.12 Other Drugs: Market Forecast, 2019-2029
6. Rare Disease Drugs Market by Applications, 2019-2029
6.1 Market Overview
6.2 Market Forecast 2019-2029
6.3 Rare Oncology Diseases Market
6.4 Rare Metabolic Diseases Market
6.5 Rare Neurologic Diseases Market
6.6 Rare Hematology Diseases Market
6.7 Rare Infectious Diseases Market
6.8 Other Rare Diseases Market
7. Rare Disease Drugs Market by Distribution Channel 2019-2029
7.1 Market Overview
7.2 Market Forecast 2019-2029
7.3 Specialty Pharmacies
7.4 Hospital Pharmacies
7.5 Retail Pharmacies
8. Rare Disease Drugs Market - Pipeline Analysis 2019-2029
8.1 Innovative Rare Disease Drugs Pipeline
8.1.1 Rare Oncology Drugs in Development
8.1.2 Rare Autoimmune Disease Drugs in Development
8.1.3 Blood-related Rare Disease Drugs in Development
8.1.4 Rare Genetic Disease Drugs in Development
8.1.5 Rare Infectious Disease Drugs in Development
9. Leading National Markets 2019-2029
9.1 Geographical Breakdown of the World Rare Disease Drugs Market
9.2 Global Rare Disease Drugs Market: Regional Forecast 2019-2029
9.3 How Will Regional Market Shares Change to 2029?
9.4 North America Rare Disease Drugs Market, 2019-2029
9.4.1 US Rare Disease Drugs Market Forecast 2019-2029
9.4.2 Canada Rare Disease Drugs Market Forecast 2019-2029
9.5 Europe Rare Disease Drugs Market, 2019-2029
9.5.1 Europe Rare Disease Drugs Market Forecast 2019-2029
9.5.2 Germany Rare Disease Drugs Market Forecast 2019-2029
9.5.3 UK Rare Disease Drugs Market Forecast 2019-2029
9.5.4 French Rare Disease Drugs Market Forecast 2019-2029
9.5.5 Italian Rare Disease Drugs Market Forecast 2019-2029
9.5.6 Spanish Rare Disease Drugs Market Forecast 2019-2029
9.6 Asia-Pacific Rare Disease Drugs Market 2019-2029
9.6.1 Japanese Rare Disease Drugs Market Forecast 2019-2029
9.6.2 Chinese Rare Disease Drugs Market 2019-2029
9.6.3 Indian Rare Disease Drugs Market 2019-2029
9.6.4 South Korea Rare Disease Drugs Market Forecast 2019-2029
9.7 RoW Rare Disease Drugs Market 2019-2029
9.7.1 Brazilian Rare Disease Drugs Market Forecast 2019-2029
9.7.2 Mexico Rare Disease Drugs Market 2019-2029
9.7.3 Russia Rare Disease Drugs Market Forecast 2019-2029
9.7.4 South Africa Rare Disease Drugs Market Forecast 2019-2029
10. Leading Companies in the Rare Disease Drugs Market
10.1 Hoffmann-La Roche Ltd.
10.1.1 Financial Overview
10.1.2 Recent Developments
10.2 AbbVie
10.2.1 Financial Overview
10.2.2 Recent Developments
10.3 Pfizer
10.3.1 Financial Overview
10.3.2 Recent Developments
10.4 Takeda Pharmaceuticals
10.4.1 Financial Overview
10.4.2 Recent Developments
10.5 Bristol-Myers Squibb Company
10.5.1 Financial Overview
10.5.2 Recent Developments
10.6 Merck & Co., Inc.
10.6.1 Financial Overview
10.6.2 Recent Developments
10.7 Novartis AG
10.7.1 Financial Overview
10.7.2 Recent Developments
10.8 Celgene Corporation
10.8.1 Financial Overview
10.8.2 Recent Developments
10.9 Teva Pharmaceuticals
10.9.1 Financial Overview
10.9.2 Recent Developments
10.10 Sanofi S.A.
10.10.1 Financial Overview
10.10.2 Recent Developments
11. Rare Disease Drugs Market, Qualitative Analysis, 2019-2029
11.1 Rare Disease Drugs Market: SWOT Analysis, 2019-2029
11.1.1 Strengths
11.1.1.1 Promising Rare Disease Drugs R&D Pipeline
11.1.1.2 Increase in Healthcare Awareness
11.1.2 Increase in Number of Drug Approvals
11.1.3 Weaknesses
11.1.4 High Research and Development Cost
11.1.5 Opportunities
11.1.6 Demand from Emerging Market Continues
11.1.7 Increase in Government Support
11.1.8 Threats
11.1.9 Uncertainty of R&D Results
11.1.10 Barriers to Market Entry
11.2 Rare Disease Drugs Market: Porters Five Forces Analysis, 2019-2029
11.2.1 Bargaining Power of Supplier: Moderate
11.2.2 Bargaining Power of Buyer: Low
11.2.3 Competitive Rivalry: High
11.2.4 The Threat of New Entrants: Low
11.2.5 Threat of Substitutes: Low
12. Conclusion
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
List of Tables
Table 2.1 List of Major Rare Oncology Diseases
Table 2.2 List of Metabolic Diseases
Table 2.3 List of Neurologic Diseases
Table 2.4 List of Hematology Diseases
Table 2.5 List of Some of the Major Other Rare Diseases
Table 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 5.1 Global Rare Disease Drugs Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 5.2 Global Revlimid Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.3 Global MabThera/Rituxan Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.4 Global Opdivo Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.5 Global Imbruvica Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.6 Global Sprycel Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.7 Global Avonex Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.8 Global Tasigna Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.9 Global Copaxone Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.10 Global Rebif Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.11 Global Gleevec Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.12 Global Velcade Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 5.13 Global Other Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.1 Global Rare Disease Drugs Market Forecast by Application: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 6.2 Global Rare Oncology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.3 Global Rare Metabolic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.4 Global Rare Neurologic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.5 Global Hematology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.6 Global Infectious Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.7 Other Rare Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.1 Global Rare Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 7.2 Global Specialty Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.3 Global Hospital Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.4 Global Retail Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 8.1 Rare Oncology Drugs in Development, 2018
Table 8.2 Rare Autoimmune Disease Drugs in Development, 2018
Table 8.3 Blood-related Rare Disease Drugs in Development, 2018
Table 8.4 Rare Genetic Disease Drugs in Development, 2018
Table 8.5 Rare Infectious Disease Drugs in Development, 2018
Table 9.1 World Rare Disease Drugs Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029
Table 9.2 Global Rare Disease Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.3 North America Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.4 North America Rare Disease Drugs Market by Region Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.5 US Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.6 Canada Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.7 Europe Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.8 Europe Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.9 Germany Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.10 UK Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.11 French Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.12 Italian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.13 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.14 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.15 Asia-Pacific Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.16 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.17 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.18 Indian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.19 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.20 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.21 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.22 Russia Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.23 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 10.1 Overview: Hoffmann-La Roche Ltd.
Table 10.2 Overview: AbbVie
Table 10.3 Overview: Pfizer
Table 10.4 Overview: Takeda Pharmaceuticals
Table 10.5 Overview: Bristol-Myers Squibb Company
Table 10.6 Overview: Merck & Co., Inc
Table 10.7 Overview: Novartis
Table 10.8 Overview: Celgene Corporation
Table 10.9 Overview: Teva Pharmaceuticals
Table 10.10 Overview: Sanofi S.A.
List of Figures
Figure 1.1 Global Rare Disease Drugs Market Segmentation Overview, 2018
Figure 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
Figure 3.2 Global Rare Disease Drugs Market Forecast Share (%) by Region 2019-2029
Figure 4.1 Rare Disease Drugs Market: Drivers 2019-2029
Figure 4.2 Rare Disease Drugs Market: Restraints 2019-2029
Figure 4.3 Rare Disease Drugs Market: Trends 2019-2029
Figure 5.1 Global Rare Disease Drugs by Drugs Market Share Forecast (%) 2019-2029
Figure 5.2 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2018
Figure 5.3 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2019
Figure 5.4 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2024
Figure 5.5 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2029
Figure 5.6 Global Revlimid Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.7 Global MabThera/Rituxan Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.8 Global Opdivo Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.9 Global Imbruvica Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.10 Global Sprycel Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.11 Global Avonex Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.12 Global Tasigna Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.13 Global Copaxone Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.14 Global Rebif Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.15 Global Gleevec Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.16 Global Velcade Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 5.17 Global Other Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.1 Global Rare Disease Drugs Market Forecast by Application Market Share (%) 2019-2029
Figure 6.2 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2018
Figure 6.3 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2024
Figure 6.4 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2029
Figure 6.5 Global Rare Oncology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.6 Global Rare Metabolic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.7 Global Rare Neurologic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.8 Global Hematology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.9 Global Infectious Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.10 Other Rare Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.1 Global Rare Disease Drugs by Distribution Channel Market Share (%) 2019-2029
Figure 7.2 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2018
Figure 7.3 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2024
Figure 7.4 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2029
Figure 7.5 Global Specialty Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.6 Global Hospital Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.7 Global Retail Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.1 Global Rare Disease Drugs Market by Region: Revenues (%), 2018
Figure 9.2 Global Rare Disease Drugs Market by Region: Revenues (%), 2024
Figure 9.3 Global Rare Disease Drugs Market by Region: Revenues (%), 2029
Figure 9.4 North America Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.5 North America Rare Disease Drugs Market by Region Forecast: Market Share 2019-2029
Figure 9.6 US Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.7 Canada Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.8 Europe Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.9 Europe Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
Figure 9.10 Germany Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.11 UK Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.12 French Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.13 Italian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.14 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.15 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.16 Asia-Pacific Rare Disease Drugs Market by Country: Revenue (%), 2019-2029
Figure 9.17 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.18 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.19 Indian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.20 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.21 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.22 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.23 Russia Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 9.24 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 10.1 Hoffmann-La Roche Ltd.: Financial Overview, 2016-2018
Figure 10.2 AbbVie: Financial Overview, 2016-2018
Figure 10.3 Pfizer: Financial Overview: 2016-2018
Figure 10.4 Takeda Pharmaceuticals: Financial Overview 2016-2018
Figure 10.5 Bristol-Myers Squibb Company: Financial Overview 2016- 2018
Figure 10.6 Merck & Co., Inc: Financial Overview 2016-2018
Figure 10.7 Novartis: Financial Overview 2016-2018
Figure 10.8 Celgene Corporation: Financial Overview 2016-2018
Figure 10.9 Teva Pharmaceuticals: Financial Overview 2016-2018
Figure 10.10 Sanofi S.A.: Financial Overview 2016-2018
Figure 11.1 SWOT Analysis of the Global Rare Disease Drugs Market, 2019-2029
Figure 12.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029
Figure 12.2 Global Rare Disease Drugs Market Forecast Share (%, By Region 2018, 2024 & 2029)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
